瘦素、脂联素及抵抗素在多囊卵巢综合征治疗中的变化  

Alteration of Serum Leptin,Adiponectin,and Resistin Levels in PCOS Patients Treated by Diane-35 alone or Combined with Metformin

作　　者：郭涛[1] 黄薇[1] 李国华[1] 王宇翮[1] 何礼霞[1] 尚晓飞[1] 

机构地区：[1]四川大学华西第二医院,四川成都610041

出　　处：《实用妇产科杂志》2007年第11期669-672,共4页Journal of Practical Obstetrics and Gynecology

摘　　要：目的:探讨血脂联素、抵抗素、瘦素及瘦素受体在多囊卵巢综合征(PCOS)抗高雄激素血症治疗和胰岛素增敏剂治疗中的变化。方法:27例PCOS患者采用达英-35(每片含醋酸环丙孕酮2mg、炔雌醇35μg)或达英-35联合二甲双胍治疗6个月,ELISA方法检测治疗前后的空腹血脂联素、抵抗素、瘦素及瘦素受体浓度,同时检测血糖和血清胰岛素、双氢睾酮(DHT)、脱氢表雄酮(DHEA)、硫酸脱氢表雄酮(DHEAs)、黄体生成激素(LH)和卵泡刺激素(FSH)等相关激素水平。结果:①所有患者的血DHT和DHEA在治疗后均明显降低(P<0.05);②单用达英-35组治疗后血抵抗素显著下降(P<0.05),血脂联素升高、瘦素受体降低,但治疗前后差异无显著性,而瘦素没有明显变化;③达英-35联合二甲双胍组治疗后,血脂联素、瘦素受体显著升高,瘦素显著下降(P<0.05),而抵抗素的下降差异无显著性。结论:脂肪细胞分泌的脂联素和瘦素在胰岛素增敏剂治疗后的明显改变,说明其可能参与PCOS胰岛素抵抗的发生发展,而抵抗素的作用尚待研究。Objective;To study the change of serum leptin and leptin receptor, adiponectin, and resistin levels in PCOS patients that treated by Diane-35 alone or Diane-35 combined Metformin. Methods：27 PCOS patients received Diane-35 alone or Diane-35 combined Metformin treatment for 6 months. The serum leptin and leptin receptor, adiponectin, and resistin levels were detected by ELISA before and after treatment, meantime, fasting plasma glucose, serum insulin and FSH, LH, T, DHT, DHEA, and DHEAs were examined. Results.The serum DHT and DHEA levels significantly decreased in all patients after treated by Diane-35 alone or with Metformin. In PCOS patients without IR, serum resistin levels significantly decreased after the Diane-35 treatment （ P〈 0.05）, but serum leptin, leptin receptor and adiponectin level had no significant change. In patients with IR, serum adiponectin and leptin receptor levels significantly increased and serum leptin levels decreased after treated by Diane-35 with Metformin （ P〈 0.05）. But serum resistin levels had no change.Conclusions：Adipocyte-derived factors leptin and adiponectin except resistin, as regulators of insulin metabolism, participates the pathogenesis of insulin resistance in PCOS.

关 键 词：多囊卵巢综合征 胰岛素抵抗 脂联素 瘦素 抵抗素 

分 类 号：R711.75[医药卫生—妇产科学]